Adagloxad Simolenin For Metastatic Breast Cancer
Adagloxad simolenin (formerly OBI-822) is a conjugate of Globo H and KLH. It is exclusively licensed to OBI from Memorial Sloan-Kettering Cancer Center (MSKCC).
Breast cancer is the most prevalent form of cancer in women. The 5-year survival rate for metastatic breast cancer is as low as 24.3%. Adagloxad simolenin, a first-in-class active immunotherapy in development for metastatic breast cancer, may fulfill this unmet medical need.
Two Phase I studies in metastatic breast cancer and relapsed prostate cancer patients, which were conducted by MSKCC, showed that Adagloxad simolenin is very safe. It was also shown to induce a strong immune response against cancer cells.